Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 365

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 365
---
 (IMM-1-104)$5,091,491 $4,591,547 $14,518,757 $12,045,176 IMM-6-415292,917 1,212,407 2,195,284 3,372,353 Other programs1,674,358 1,164,557 4,093,993 4,699,070 Non-program expenses(2)1,894,410 1,380,336 4,677,209 4,223,505 Employee-related costs4,892,610 5,195,836 15,216,089 16,126,828 Stock-based compensation expense1,456,080 1,640,116 4,673,290 4,776,623 Depreciation and amortization78,841 88,949 248,628 269,691 Other segment items(3)(415,832)(676,382)(1,178,362)(2,528,123)Net loss$14,964,875 $14,597,366 $44,444,888 $42,985,123 (1) Includes direct research and development expenses.(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.(3) Includes interest income and other (income) expense.

Note 12 – Subsequent EventsOctober 2025 Pre-Funded Warrant ExerciseOn October 6, 2025, certain purchasers from the August 2025 Private Placement exercised an aggregate of 1,077,764 Pre-Funded Warrants previously issued to them pursuant to the August 2025 Purchase Agreement. Each such exercise was made pursuant to the cashless exercise provision of the applicable Pre-Funded Warrant, such that an aggregate of 166 shares of common stock were withheld in lieu of cash payment of the $0.001 exercise price for each Pre-Funded Warrant share, and the exercising purchasers were issued an aggregate of 1,077,598 shares of common stock (the "October 2025 Cashless Exercise"). Following the October 2025 Cashless Exercise, no Pre-Funded Warrants remained issued and outstanding.

26

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements